20 years of Cure Parkinson's
We’re here for the cure! This year marks 20 years since Cure Parkinson’s was founded by four people living with Parkinson’s who felt that nobody was taking a cure seriously enough and that there was an urgent need for a focused approach to curative research...
Learn more
New potential drugs for repurposing in Parkinson’s
The development of new drugs is a long and expensive process, taking many years of funding to bring new therapeutics to treat diseases. Drug repurposing offers a means of rapidly testing already available medicines in diseases that they were not originally approved for.
Repurposing bumetanide for Alzheimer’s
Bumetanide (Bumex) is a diuretic drug (a medication that removes water, by increasing the production of urine). It is used to treat swelling caused by heart failure or liver or kidney disease. It is a widely used drug that has been well characterised in clinical use. Recently researchers conducted a screening […]
Patron Mike Tindall speaks to four families affected by Parkinson’s on BBC Breakfast with Sally Nugent
In a poignant piece for BBC Breakfast, Cure Parkinson’s patron Mike Tindall and BBC presenter Sally Nugent met with Alison Anderson, Amarpal Harrar, Omotola Thomas and David Murray, all of whom are living with Parkinson’s.
‘Sport Parkinson’s Four Nations Golf Tournament’ tees off at The Belfry
From 11-13 October, four teams of golfers who have Parkinson’s, from the four UK nations, will tee off on The Belfry’s Brabazon course for two days of friendly competition and fundraising. Cure Parkinson’s patron, Mike Tindall, will lead the England team.
Making a (G)case for quetiapine
Drug repurposing (repositioning, reprofiling or re-tasking) is a strategy of identifying novel uses for clinically approved (or experimental) drugs that fall outside the scope of the original medical indication. Many drug repurposing efforts have started with screening experiments, looking for drugs with certain properties. Recently, researchers conducted a drug repurposing screening […]